Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Faulding Inc.
Mylan's New Focus
For most of the 1990s, Mylan Laboratories was the dominant US generics manufacturer both in terms of financial performance and creative competitive strategies. But it seems to have lost its way a bit and is struggling to regain its competitive edge in an industry that no longer reflects the world it grew up in. Revenues grew a sluggish 7% to $846 million in 2001, in part because efforts to diversify into proprietary drugs haven't met goals. In June, two top executives left, both of whom had been there only a short time.
- Medical Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.